cyclophosphamide + fludarabine + plerixafor

This is a combination regimen consisting of three drugs—cyclophosphamide, fludarabine, and plerixafor—used primarily in the context of hematopoietic stem cell mobilization and conditioning for transplantation. Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell death; fludarabine is a purine analog that inhibits DNA synthesis; and plerixafor is a small molecule antagonist of the chemokine receptor CXCR4, which disrupts the interaction between stromal-derived factor-1 (SDF-1/CXCL12) and CXCR4 to mobilize hematopoietic stem cells from bone marrow into peripheral blood. This combination may be used as part of preparative regimens for allogeneic or autologous stem cell transplantation in patients with hematological malignancies such as chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), or multiple myeloma. The addition of plerixafor can enhance stem cell yield when standard mobilization strategies are insufficient[1][2][4].